Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dermatomyositis: diagnosis, evaluation and management.

J P Callen1

  • 1Division of Dermatology, University of Louisville, School of Medicine, Louisville, KY, USA. jefca@aol.com

Minerva Medica
|July 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-C1q antibodies in systemic lupus erythematosus.

Lupus·2014
Same author

Hypertrophic lupus erythematosus complicating long-standing systemic lupus erythematosus.

Lupus·2011
Same author

Drug-induced subacute cutaneous lupus erythematosus.

Lupus·2010
Same author

Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus.

Lupus·2004
Same author

Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

Clinical and experimental dermatology·2004
Same author

Update on the management of cutaneous lupus erythematosus.

The British journal of dermatology·2004

Dermatomyositis (DM) is a rare autoimmune disease affecting skin and muscles. Early diagnosis and treatment are crucial for managing symptoms and improving prognosis, though residual weakness can persist.

Area of Science:

  • Rheumatology
  • Dermatology
  • Internal Medicine

Background:

  • Dermatomyositis (DM) is a systemic autoimmune condition primarily affecting the skin and muscles.
  • Adult DM is notably associated with an increased risk of malignancy, necessitating thorough patient evaluation.
  • Systemic involvement can extend to esophageal, pulmonary, and cardiac systems.

Purpose of the Study:

  • To provide a comprehensive overview of dermatomyositis, including its systemic manifestations.
  • To outline current therapeutic strategies for both the myopathic and cutaneous components of DM.
  • To discuss prognostic factors and potential long-term sequelae in DM patients.

Main Methods:

  • Review of existing literature on dermatomyositis diagnosis, treatment, and prognosis.

Related Experiment Videos

  • Synthesis of information regarding the management of muscle and skin symptoms.
  • Analysis of factors influencing patient outcomes, including comorbidities and malignancy association.

    • Main Results:

    • Effective treatments for DM myopathy include corticosteroids, immunosuppressives, biologics, and immune globulin.
    • Cutaneous manifestations are managed with sun protection, topical corticosteroids, antimalarials, and methotrexate.
    • Prognosis is generally favorable but can be complicated by malignancy, severe weakness, or cardiopulmonary dysfunction.

    Conclusions:

    • Dermatomyositis requires a multidisciplinary approach, addressing both its primary symptoms and potential systemic complications.
    • While treatments can control disease activity, residual weakness remains a concern for many patients.
    • Vigilant monitoring for associated conditions, particularly malignancy, is essential throughout the patient's care journey.